Publications

Publications

Scientific foundation of glycoengineering in biologics

Glyvantis Bio’s platform is supported by peer-reviewed research in antibody glycosylation, CHO cell metabolism and galactosylation control. These publications demonstrate how glycan structure influences antibody function, stability and clinical performance.

Glyvantis

  1. NEW! – Aquino, et al. 2026. Computationally inspired glycoengineering to maximise mAb β4-galactosylation,Metabolic Engineering, Volume 99, 2027, 102549
  2. Jiménez del Val, et al., 2023, CHOmpact: A reduced metabolic model of Chinese hamster ovary cells with enhanced interpretability

Galactosylation as a major source of mAb variability

  1. Luo et al., 2026. Glycan profiles of FDA-approved therapeutic antibodies: insights from regulatory submissions. AAPS J 28, 53
  2. Raju et al., 2012. Galactosylation variations in marketed therapeutic antibodies. mAbs 4(3):385-391

Galactosylation enhances ADCC, CDC, and ADCP

  1. Khuns et al., 2020. Differential influence on antibody-dependent cellular phagocytosis by different glycoforms on therapeutic monoclonal antibodies. J Biotechnol 317:5-15
  2. Peschke et al., 2017. Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol 8:646
  3. Thomann et al., 2016. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol 73:69-75